background
Jill Durocher

If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion

Published
September 1st, 2015
Type
Publication
Topic
Medical Abortion
Authors
Gold, M., Chong, E.
Downloads

Contraception; 2015 Sep; 92(3):194-6; doi:10.1016/j.contraception.2015.06.011

Given the highly political nature of abortion in the United States, the provision of medical abortion with mifepristone and misoprostol has always occurred under a unique set of circumstances and restrictions. The current FDA-approved medical abortion regimen requires clinicians to administer mifepristone in the office, and requires women to return to the office for the misoprostol. Six studies, enrolling over 1800 women, found that the option of taking mifepristone out of the office was popular and acceptable among women and providers.